Developmental Therapeutics Program

The mission of the Developmental Therapeutics Program, at the Alabama Center for Childhood Cancer and Blood Disorders, is to identify and develop new therapies for children and young adults with cancer. Our ultimate goal is to improve the cure rate of pediatric cancers while also decreasing immediate and long-term side effects experienced by children undergoing treatment. Patients referred to the Developmental Therapeutics Program typically have recurrent or refractory malignancies that have failed standard therapies. Other patients may be diagnosed with rare tumors for which no effective therapies have been established.

As one of only 21 premier pediatric oncology programs in the country that were selected through a peer review by the Children’s Oncology Group Phase 1 and Pilot Consortium, we are able to provide patients access to innovative therapies not widely available. The Developmental Therapeutics Program is also a member of the Neurofibromatosis Consortium, the Head Start Consortium, and Sarcoma Alliance for Research through Collaboration (SARC). Additionally, we work with the pharmaceutical industry and with the diverse scientific community at the University of Alabama at Birmingham (UAB). Studies currently open and accruing patients are listed below.

Ongoing collaborations include bench to bedside clinical trials of promising new agents or combinations of agents to treat pediatric cancers including brain tumors, neuroblastoma, osteosarcoma, rhabdomyosarcoma, and leukemia. By combining the innovation and expertise of the UAB Division of Pediatric Hematology-Oncology, Children’s of Alabama, and researchers from UAB and around the world, the Developmental Therapeutics Program offers cutting-edge therapies and state-of-the-art care while helping to advance the treatment of pediatric cancers for generations to come.

For more information, contact: Developmental Therapeutics Research Nurse Manager Bridget Tate, RN MSN at 205-638-2984 or btate@peds.uab.edu

Alyssa T. Reddy, M.D.
Professor of Pediatrics, Neurology, and Surgery
Director, Neuro-Oncology and Developmental Therapeutics
UAB Division of Pediatric Hematology-Oncology


Developmental Therapeutics Studies currently open to patient accrual

Phase I Clinical Trial of HSV G207 Alone or With a Single Radiation Dose in Children with Recurrent Supratentorial Brain Tumors (this would link to neuro-onc page)
UAB 1472 HSV G207 Study Synopsis for Healthcare Professionals (PDF)
UAB 1472 HSV G207 Patient and Family Summary (PDF)

ADVL1212 — A Phase 1 Study of Crizotinib (IND# 105573) in Combination with Conventional Chemotherapy for Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma.

  • For patients with relapsed or refractory solid tumors or anaplastic large cell lymphoma
  • Eligibility:
    • Ages 1- 21.
    • Participant cannot have primary or metastatic CNS tumor.
    • Participant must not have previously received crizotinib therapy.

ADVL1312 — A Phase 1/2 Study of AZD1775 (MK-1775, IND# 121422) in Combination with Oral Irinotecan in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors

  • For patients with relapsed or refractory solid tumors
  • Eligibility:
    • Ages 1 to 21
    • Diagnosis of solid tumor that is resistant to other anticancer therapy or has come back after therapy. Includes lymphoma and central nervous system (CNS) tumors that may or may not require surgery.
    • Must be able to swallow tablets whole

ADVL1314 — A Phase 1 Study of Eribulin Mesylate (E7389, IND#116,292), a Novel Microtubule Targeting Chemotherapeutic Agent in Children with Refractory or Recurrent Solid Tumors (excluding CNS), including Lymphomas.

  • For patients with refractory or recurrent solid tumors or lymphomas
  • Eligibility:
    • Ages 6 months to 18 years.
    • Patients with primary CNS tumors are not eligible
    • Must not have received prior therapy with eribulin mesylate

ADVL1315 — A Phase 1 Study of the VEGF Receptor Tyrosine Kinase Inhibitor Axitinib (INLYTA, IND# 123101) in Children with Recurrent or Refractory Solid Tumors

  • For patients with refractory or recurrent solid tumors OR unresectable translocation positive renal cell carcinoma (tRCC) are
  • Eligibility:   
    • Ages 1-18
    • Patients must be able to swallow tablets whole
    • Patients with known primary or metastatic CNS tumor are excluded

ADVL1411 — A Phase 1/2 Study of BMN 673 (IND #121510), an Oral Poly(ADP-ribose) Polymerase Inhibitor, Plus Temozolomide in Children with Refractory or Recurrent Malignancies

  • For patients with relapsed or refractory solid tumors, Ewing sarcoma or Peripheral PNET without bone marrow involvement
  • And patients with Acute Lymphoblastic Leukemias (ALL) who have had at least 2 relapses of pre-B ALL or T-cell ALL
  • Eligibility
    • Ages 1 to 21
    • Patients must be able to swallow capsules whole.
    • Patients who have progressed on a PARP inhibitor and temozolomide regimen are not eligible

ADVL1412 — A Phase 1/2 Study of Nivolumab (IND#124729) in Children, Adolescents, and Young Adults with Recurrent or Refractory Solid Tumors as a Single Agent and in Combination with Ipilimumab

  • For patients with recurrent or refractory
    • solid tumors
    • neuroblastoma
    • osteosarcoma
    • rhabdomyosarcoma
    • Ewing Sarcoma or
    • Peripheral PNET
    • Hodgkin Lymphoma
    • Non-Hodgkin Lymphoma
    • melanoma (or unresectable or metastatic melanoma)
    • neuroblastoma
  • Eligibility:
    • Ages 1 -18 (Some patients under age 30 may qualify) 
    • Patients with CNS tumors or known CNS metastases are not eligible.
    • Patients with a history of any Grade autoimmune disorder are not eligible

ADVL1414 — A Phase 1 Study of Selinexor (KPT-330, IND #125052), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, including CNS Tumors

  • For Solid Tumors
  • Eligibility:
    • Ages 1 to 21
    • Diagnosis of solid tumor that is resistant to other anticancer therapy or has come back after therapy, including lymphoma and central nervous system (CNS) tumors
    • Fully recovered from the effects of all prior anticancer therapy
    • Must be able to swallow tablets whole

ADVL1416 — A Phase 1 study of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children with Refractory Solid tumors, including CNS Tumors

  • For patients with recurrent or refractory CNS tumors or non-CNS solid tumors
  • Eligibility:
    • Ages 1-21
    • Patients who are chronically receiving aspirin, ibuprofen or other non-steroidal anti-inflammatory drugs are not eligible
    • Patients who are receiving anti-hypertensive medications for control of blood pressure at the time of enrollment are not eligible for this trial.

ADVL1522 — A Phase 2 Study of IMGN901 (Lorvotuzumab Mertansine; IND# 126953, NSC# 783609) in Children with Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor (MPNST) and Synovial Sarcoma

  • For patients with relapsed or refractory:
    • Wilms tumor
    • Rhabdomyosarcoma
    • Neuroblastoma
    • Pleuropulmonary blastoma
    • Malignant peripheral nerve sheath tumor (MPNST)
    • Synovial sarcoma
  • Eligibility:
    • Age 1 – 30
    • Patients must not have known active CNS metastases or with a CNS toxicity > Grade 2 are not eligible

AOST1521 — A Phase 2 Study of GPNMB-targeted Antibody-Drug Conjugate, CDX-011 (Glembatumumab Vedotin, CR011-vcMMAE; IND# 128248, NSC# 763737), in Recurrent or Refractory Osteosarcoma

  • For patients with recurrent or refractory osteosarcoma
  • Eligibility:
    • Ages 12- 50
    • Patients with known central nervous system metastasis are not eligible

Donate to Hematology & Oncology